{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:50:58Z","timestamp":1794383458732,"version":"4.9.0"},"reference-count":195,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Spain","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Patients with immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis and inflammatory bowel disease, are at increased risk of infection. International guidelines recommend vaccination to limit this risk of infection, although live attenuated vaccines are contraindicated once immunosuppressive therapy has begun. Biologic therapies used to treat IMIDs target the immune system to stop chronic pathogenic process but may also attenuate the protective immune response to vaccines. Here, we review the current knowledge regarding vaccine responses in IMID patients receiving treatment with biologic therapies, with a focus on the interleukin (IL)-12\/23 inhibitors. B cell-depleting therapies, such as rituximab, strongly impair vaccines immunogenicity, and tumor necrosis factor (TNF) inhibitors and the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) fusion protein abatacept are also associated with attenuated antibody responses, which are further diminished in patients taking concomitant immunosuppressants. On the other hand, integrin, IL-6, IL-12\/23, IL-17, and B-cell activating factor (BAFF) inhibitors do not appear to affect the immune response to several vaccines evaluated. Importantly, treatment with biologic therapies in IMID patients is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or developing severe disease. However, the efficacy of SARS-CoV-2 vaccines on IMID patients may be reduced compared with healthy individuals. The impact of biologic therapies on the response to SARS-CoV-2 vaccines seems to replicate what has been described for other vaccines. SARS-CoV-2 vaccination appears to be safe and well tolerated in IMID patients. Attenuated but, in general, still protective responses to SARS-CoV-2 vaccination in the context of certain therapies warrant current recommendations for a third primary dose in IMID patients treated with immunosuppressive drugs.<\/jats:p>","DOI":"10.3390\/vaccines10020297","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:44:57Z","timestamp":1644965097000},"page":"297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Beatriz","family":"Garcill\u00e1n","sequence":"first","affiliation":[{"name":"Medical Affairs Department, Janssen, 28042 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Salavert","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Department of Clinical Medicine, La Fe Health Research Institute, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-7762","authenticated-orcid":false,"given":"Jos\u00e9 R.","family":"Regueiro","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 12 de Octubre Health Research Institute (imas12), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"D\u00edaz-Castroverde","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Janssen, 28042 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.13101","article-title":"Genetics of immune-mediated inflammatory diseases","volume":"193","author":"David","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2050640619889763","article-title":"Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines","volume":"8","author":"Wisniewski","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/BOR.0000000000000598","article-title":"Prediction of infection risk in rheumatoid arthritis patients treated with biologics: Are we any closer to risk stratification?","volume":"31","author":"Jani","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjd.17421","article-title":"Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy","volume":"180","author":"Yiu","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical Guideline: Preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114184","DOI":"10.1016\/j.bcp.2020.114184","article-title":"COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials","volume":"180","author":"Chakraborty","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: An overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","article-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis","volume":"22","author":"Hagberg","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ibd\/izy243","article-title":"Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease","volume":"25","author":"Tinsley","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ibrahim, A., Ahmed, M., Conway, R., and Carey, J.J. (2019). Risk of infection with methotrexate therapy in inflammatory diseases: A systematic review and meta-analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010015"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjd.15377","article-title":"Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"177","author":"Mazaud","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (soluble immune effector molecules [I]: Anti-tumor necrosis factor-alpha agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (soluble immune effector molecules [II]: Agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","first-page":"2958","article-title":"Efficacy and safety of IL-17 inhibitors for patients with psoriatic arthritis: A systematic review and meta-analysis","volume":"25","author":"Gao","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Michielin","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Bellinato, F., Chiricozzi, A., and Girolomoni, G. (2020). The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines, 8.","DOI":"10.3390\/vaccines8040728"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.dld.2020.12.013","article-title":"Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population","volume":"53","author":"Maconi","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: Recommendations from an international consensus meeting","volume":"70","author":"Siegel","year":"2021","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"FAI2R\/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE Consortium and Contributors (2020). Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann. Rheum. Dis., 80, 527\u2013538.","DOI":"10.1136\/annrheumdis-2020-218310"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2050640620972602","article-title":"Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"9","author":"Singh","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","article-title":"Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab","volume":"80","author":"Krueger","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.dld.2020.12.120","article-title":"Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs","volume":"53","author":"Bossa","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.cgh.2020.08.003","article-title":"Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: It is time to take stock","volume":"18","author":"Danese","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e14204","DOI":"10.1111\/dth.14204","article-title":"Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic","volume":"33","author":"Giuliani","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Gisondi, P., Bellinato, F., and Girolomoni, G. (2020). Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines, 8.","DOI":"10.3390\/vaccines8040769"},{"key":"ref_38","first-page":"507","article-title":"Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-alpha therapy","volume":"34","author":"Caso","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ad.2016.04.017","article-title":"Expert recommendations on treating psoriasis in special circumstances (part II)","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Serrano, C., Mirada, G., Marsal, J.R., Ortega, M., Sol, J., Solano, R., Artigues, E.M., and Estany, P. (2020). Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: Implications on public health policies. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-08850-y"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Commelin, D.J.A., Sindelar, R.D., and Meibohm, B. (2019). Vaccines. Pharmaceutical Biotechnology: Fundamentals and Applications, Springer Nature. [5th ed.].","DOI":"10.1007\/978-3-030-00710-2"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of multivalency and antigenic threshold in generating protective antibody responses","volume":"10","author":"Slifka","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e00084-18","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_50","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: A randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13075-015-0863-3","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Alten, R., Bingham, C.O., Cohen, S.B., Curtis, J.R., Kelly, S., Wong, D., and Genovese, M.C. (2016). Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet. Disord., 17.","DOI":"10.1186\/s12891-016-1082-z"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Saxne","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Richi, P., Yuste, J., Nav\u00edo, T., Gonz\u00e1lez-Hombrado, L., Salido, M., Thuissard-Vasallo, I., Jim\u00e9nez-D\u00edaz, A., Llorente, J., Cebri\u00e1n, L., and Lojo, L. (2021). Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases. Vaccines, 9.","DOI":"10.3390\/vaccines9030203"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10067-020-05042-2","article-title":"Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: Results of the RIER cohort study","volume":"39","author":"Richi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Holvast","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12390","article-title":"Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients","volume":"178","author":"Westra","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.medcli.2019.02.003","article-title":"Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study","volume":"153","author":"Richi","year":"2019","journal-title":"Med. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of A\/H1N1 vaccination in immune-mediated disease\u2014A prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","first-page":"1356","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: Results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_72","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_73","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn\u2019s disease","volume":"33","author":"Kantso","year":"2015","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.crohns.2013.09.022","article-title":"Patients with Crohn\u2019s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine","volume":"8","author":"Lee","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_77","first-page":"595","article-title":"Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease","volume":"70","author":"Meek","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jbspin.2015.10.017","article-title":"Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept","volume":"83","author":"Rakoczi","year":"2016","journal-title":"Jt. Bone Spine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/jgh.13001","article-title":"Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients","volume":"30","author":"Andrade","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/MEG.0000000000000370","article-title":"Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases","volume":"27","author":"Belle","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","article-title":"Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Franca","year":"2012","journal-title":"Rheumatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/s10165-007-0632-5","article-title":"Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis","volume":"17","author":"Kubota","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"ref_88","first-page":"181","article-title":"Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis","volume":"33","author":"Polachek","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.crohns.2013.08.008","article-title":"Infliximab and\/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease","volume":"8","author":"Hagihara","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","article-title":"Immune response to influenza A\/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: Effects of combined therapy with immunosuppressants","volume":"7","author":"Andrisani","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjv152","article-title":"Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and\/or biologics: A two-year prospective study","volume":"9","author":"Launay","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/08916934.2012.750300","article-title":"AID in aging and autoimmune diseases","volume":"46","author":"Frasca","year":"2013","journal-title":"Autoimmunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.vaccine.2009.02.053","article-title":"Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible","volume":"27","author":"Gelinck","year":"2009","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","article-title":"Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept","volume":"48","author":"Borte","year":"2009","journal-title":"Rheumatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/CVI.00386-12","article-title":"Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomized single-center study","volume":"19","author":"Chioato","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e001018","DOI":"10.1136\/rmdopen-2019-001018","article-title":"Secukinumab does not impair the immunogenic response to the influenza vaccine in patients","volume":"5","author":"Richi","year":"2019","journal-title":"RMD Open"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40259-017-0249-y","article-title":"Response to tetanus and pneumococcal vaccination following administration of ixekizumab in healthy participants","volume":"31","author":"Gomez","year":"2017","journal-title":"BioDrugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: Results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"72","author":"Mori","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/14397595.2013.843743","article-title":"Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab","volume":"24","author":"Tsuru","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis","volume":"71","author":"Mori","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_105","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use","volume":"12","author":"Brodmerkel","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_106","first-page":"677","article-title":"Effects of ustekinumab administration on primate\/human antigen-recall and humoral immune response functions","volume":"9","author":"Brodmerkel","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Doornekamp, L., Goetgebuer, R.L., Schmitz, K.S., Goeijenbier, M., van der Woude, C.J., Fouchier, R., van Gorp, E.C.M., and de Vries, A.C. (2020). High immunogenicity to influenza vaccination in Crohn\u2019s disease patients treated with ustekinumab. Vaccines, 8.","DOI":"10.3390\/vaccines8030455"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: Biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-013-0080-9","article-title":"Abatacept: A review of its use in the management of rheumatoid arthritis","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-020-0410-x","article-title":"Maintenance of antibody response to diphtheria\/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept","volume":"18","author":"Brunner","year":"2020","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: Advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Commelin, D.J.A., Sindelar, R.D., and Meibohm, B. (2019). Antibody-based therapeutics in inflammatory diseases. Pharmaceutical Biotechnology: Fundamentals and Applications, Springer Nature. [5th ed.].","DOI":"10.1007\/978-3-030-00710-2"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J. Cutan Med. Surg."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: A fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_118","first-page":"416","article-title":"Targeting B cells for the treatment of SLE: The beginning of the end or the end of the beginning?","volume":"10","author":"Calero","year":"2010","journal-title":"Discov. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Steeland, S., Libert, C., and Vandenbroucke, R.E. (2018). A new venue of TNF targeting. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201804.0015.v1"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis","volume":"36","author":"Langedijk","year":"2018","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: A randomized trial","volume":"22","author":"Fonseca","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1016\/j.vaccine.2008.04.028","article-title":"Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine","volume":"26","author":"Gelinck","year":"2008","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2020.04.025","article-title":"Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study","volume":"156","author":"Richi","year":"2021","journal-title":"Med. Clin."},{"key":"ref_130","first-page":"393","article-title":"Effectiveness of childhood vaccinations in CAPS patients treated with canakinumab: Results from an open-label phase III extension study [abstract THU0495]","volume":"69","author":"Brogan","year":"2015","journal-title":"Arthritis Rheum."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"ftw111","DOI":"10.1093\/femspd\/ftw111","article-title":"Cytokines IL-17 and IL-22 in the host response to infection","volume":"74","author":"Valeri","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-065X.2008.00699.x","article-title":"The roles of IL-17A in inflammatory immune responses and host defense against pathogens","volume":"226","author":"Iwakura","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6145810","DOI":"10.1155\/2016\/6145810","article-title":"Enigma of IL-17 and Th17 cells in rheumatoid arthritis and in autoimmune animal models of arthritis","volume":"2016","author":"Kugyelka","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting edge: Homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 Inhibition for the management of rheumatoid arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: Designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: Room for discovery","volume":"50","author":"Hunter","year":"2019","journal-title":"Immunity"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","article-title":"Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells","volume":"177","author":"Manetti","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Floss, D.M., Moll, J.M., and Scheller, J. (2020). IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions. Cells, 9.","DOI":"10.3390\/cells9102184"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2012-08-448902","article-title":"IL-12 receptor beta1 deficiency alters in vivo T follicular helper cell response in humans","volume":"121","author":"Schmitt","year":"2013","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.immuni.2009.04.016","article-title":"Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12","volume":"31","author":"Schmitt","year":"2009","journal-title":"Immunity"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1128\/CVI.00090-08","article-title":"Influenza virus vaccination induces interleukin-12\/23 receptor beta 1 (IL-12\/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12\/23R beta 1 or IFN-gamma receptor I","volume":"15","author":"Kuijpers","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"eaau6759","DOI":"10.1126\/sciimmunol.aau6759","article-title":"Human IFN-\u03b3 immunity to mycobacteria is governed by both IL-12 and IL-23","volume":"3","author":"Markle","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/humu.22380","article-title":"IL-12R\u00df1 deficiency: Mutation update and description of the IL12RB1 variation database","volume":"34","author":"Haverkamp","year":"2013","journal-title":"Hum. Mutat."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MD.0b013e3181fdd832","article-title":"Revisiting human IL-12Rbeta1 deficiency: A survey of 141 patients from 30 countries","volume":"89","author":"Samarina","year":"2010","journal-title":"Medicine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1084\/jem.20080840","article-title":"ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity","volume":"205","author":"Odegard","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/blood-2011-11-392985","article-title":"Functional STAT3 deficiency compromises the generation of human T follicular helper cells","volume":"119","author":"Ma","year":"2012","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Uddin, M., Mustafa, F., Rizvi, T.A., Loney, T., Suwaidi, H.A., Al-Marzouqi, A.H.H., Eldin, A.K., Alsabeeha, N., Adrian, T.E., and Stefanini, C. (2020). SARS-CoV-2\/COVID-19: Viral genomics, epidemiology, vaccines, and therapeutic interventions. Viruses, 12.","DOI":"10.20944\/preprints202004.0005.v1"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Deepak, P., Kim, W., Paley, M.A., Yang, M., Carvidi, A.B., El-Qunni, A.A., Haile, A., Huang, K., Kinnett, B., and Liebeskind, M.J. (2021). Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv, preprint.","DOI":"10.1101\/2021.04.05.21254656"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Kaplan","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2665-9913(21)00186-7","article-title":"Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"3","author":"Vuilleumier","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Bugatti, S., De Stefano, L., Balduzzi, S., Greco, M.I., Luvaro, T., Cassaniti, I., Bogliolo, L., Mazzucchelli, I., D\u2019Onofrio, B., and di Lernia, M. (2021). Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann. Rheum Dis., online ahead of print June 25.","DOI":"10.1136\/annrheumdis-2021-220862"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Littlewood","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e001847","DOI":"10.1136\/rmdopen-2021-001847","article-title":"Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors","volume":"8","author":"Venerito","year":"2022","journal-title":"RMD Open"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Cristaudo, A., Graceffa, D., Pimpinelli, F., Sperati, F., Spoletini, G., Bonifati, C., Pellini, R., Lora, V., Pontone, M., and Di Bella, O. (2021). Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.3389\/fmed.2022.961904"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: A cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: A longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_170","first-page":"1","article-title":"Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease-results of a single-center cohort study in a tertiary hospital in Germany","volume":"10","author":"Classen","year":"2021","journal-title":"Dig. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2021.06.016","article-title":"Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease","volume":"161","author":"Kappelman","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Kappelman, M.D., Weaver, K.N., Zhang, X., Dai, X., Watkins, R., Adler, J., Dubinsky, M.C., Kastl, A., Bousvaros, A., and Strople, J.A. (2021). Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases. Am. J. Gastroenterol., online ahead of print December 29.","DOI":"10.14309\/ajg.0000000000001619"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Charilaou, P., Tricarico, C., Battat, R., Scherl, E.J., Longman, R.S., and Lukin, D.J. (2021). Impact of inflammatory bowel disease therapies on durability of humoral response to SARS-CoV-2 vaccination. Clin. Gastroenterol. Hepatol., online ahead of print December 9.","DOI":"10.1016\/j.cgh.2021.12.007"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Frey, S., Chowdhury, R., Connolly, C.M., Werbel, W.A., Segev, D.L., Parian, A.M., IBD Group, Tsipotis, E., Dudley-Brown, S., and Lazarev, M. (2022). Antibody response six months after SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol., online ahead of print January 5.","DOI":"10.1016\/j.cgh.2021.12.045"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Shehab, M., Alrashed, F., Alfadhli, A., Alotaibi, K., Alsahli, A., Mohammad, H., Cherian, P., Al-Khairi, I., Alphonse Thanaraj, T., and Channanath, A. (2021). Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies. Vaccines, 9.","DOI":"10.1101\/2021.10.31.21265718"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Lin, S., Kennedy, N.A., Saifuddin, A., Mu\u00f1oz Sandoval, D., Reynolds, C., Castro Seoane, R., Kottoor, S., Pieper, F., Lin, K.-M., and Butler, D.K. (2021). COVID-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients. Res. Sq., preprint.","DOI":"10.21203\/rs.3.rs-755879\/v1"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Reuken, P.A., Andreas, N., Grunert, P.C., Glockner, S., Kamradt, T., and Stallmach, A. (2021). T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease. J. Crohns Colitis, online ahead of print Aug 11.","DOI":"10.1093\/ecco-jcc\/jjab147"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Li, D., Xu, A., Mengesha, E., Elyanow, R., Gittelman, R.M., Chapman, H., Prostko, J.C., Frias, E.C., Stewart, J.L., and Pozdnyakova, V. (2021). The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders. medRxiv, preprint.","DOI":"10.1101\/2021.12.08.21267444"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.gastro.2021.06.076","article-title":"BNT162b2 messenger RNA COVID-19 vaccine effectiveness in patients with inflammatory bowel disease: Preliminary real-world data during mass vaccination campaign","volume":"161","author":"Banon","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e15177","DOI":"10.1111\/dth.15177","article-title":"Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience","volume":"35","author":"Musumeci","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Weaver, K.N., Zhang, X., Dai, X., Watkins, R., Adler, J., Dubinsky, M.C., Kastl, A., Bousvaros, A., Strople, J.A., and Cross, R.K. (2021). Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: Results from PREVENT-COVID. Inflamm. Bowel Dis., izab302.","DOI":"10.1093\/ibd\/izab302"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Botwin, G.J., Li, D., Figueiredo, J., Cheng, S., Braun, J., McGovern, D.P.B., and Melmed, G.Y. (2021). Adverse events following SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. medRxiv, preprint.","DOI":"10.1101\/2021.03.30.21254607"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Li, D., Debbas, P., Cheng, S., Braun, J., McGovern, D.P.B., and Melmed, G.Y. (2021). Post-vaccination symptoms after a third dose of mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease. medRxiv, preprint.","DOI":"10.1101\/2021.12.05.21266089"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Hadjadj, J., Planas, D., Ouedrani, A., Buffier, S., Delage, L., Nguyen, Y., Bruel, T., Stolzenberg, M.C., Staropoli, I., and Ermak, N. (2022). Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann. Rheum. Dis., online ahead of print January 12.","DOI":"10.1101\/2021.08.08.21261766"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Simon, D., Tascilar, K., Fagni, F., Schmidt, K., Kronke, G., Kleyer, A., Ramming, A., Schoenau, V., Bohr, D., and Knitza, J. (2021). Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann. Rheum. Dis., online ahead of print November 24.","DOI":"10.1136\/annrheumdis-2021-221554"},{"key":"ref_189","unstructured":"American Academy of Dermatology (2021, March 19). COVID-19 Vaccine Administration Guidance. Available online: https:\/\/assets.ctfassets.net\/1ny4yoiyrqia\/2gTpp7G9GNSTtAHwPHNtbc\/b23a62ab746ad4672158a0c9633ca7aa\/COVID_vaccine_administration_guidance_2-15-21.pdf."},{"key":"ref_190","unstructured":"European Academy of Dermatology and Venereology (2021, March 19). COVID-19 Vaccination: Advice of the EADV Task Forces. Available online: https:\/\/www.eadv.org\/index.php\/cms-admin\/showfile\/COVID-19%20VACCINATION%20-%20TF%20ADVICE_02-10-2021-13-12-40.pdf."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel disease: A British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement","volume":"6","author":"Alexander","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_192","unstructured":"American College of Rheumatology (2021, March 19). COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Available online: https:\/\/www.rheumatology.org\/Portals\/0\/Files\/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf."},{"key":"ref_193","unstructured":"European Medicines Agency (2022, January 25). Comirnaty and Spikevax: EMA Recommendations on Extra Doses and Boosters. Available online: https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-spikevax-ema-recommendations-extra-doses-boosters."},{"key":"ref_194","unstructured":"Department of Health & Social Care (2022, January 25). Joint Committee on Vaccination and Immunisation (JCVI) Advice on Third Primary Dose Vaccination, Available online: https:\/\/www.gov.uk\/government\/publications\/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice\/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination."},{"key":"ref_195","unstructured":"Centers for Disease Control and Prevention (2022, January 25). Considerations for COVID-19 Vaccination in Moderately or Severely Immunocompromised People, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html#considerations-covid19-vax-immunocopromised."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:02Z","timestamp":1760134802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":195,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020297"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020297","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}